Sugi Predict

Sugi Predict / Compounds / SCHEMBL269332

SCHEMBL269332

SCHEMBL269332

CC(C)c1cccnc1C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 3/20 0.46
▸ GABRB2 P47870 2/20 0.46
▸ TSHR P16473 3/20 0.42
▸ GABRG2 P18507 2/20 0.42
▸ GABRB3 P28472 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ FAAH O00519 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ PTGS1 P23219 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ GABRA2 P47869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28822995 0.98 GABRA1 (0.44) GABRA1GABRB2TSHRGABRG2GABRB3
Alcohol SCHEMBL27794349 0.89 GABRA1 (0.45) GABRA1GABRB2TSHRGABRG2GABRB3
Formamide SCHEMBL9540188 0.88 CHRNA7 (0.40) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL25018223 0.87 GABRA1 (0.40) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL22961377 0.87 GABRA1 (0.40) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL22678974 0.87 GABRA1 (0.40) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL20350128 0.87 GABRA1 (0.40) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL22212336 0.85 GABRA1 (0.43) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL13713003 0.84 GABRA1 (0.41) GABRA1GABRB2TSHRGABRG2GABRB3
SCHEMBL11887368 0.84 GABRA1 (0.37) GABRA1GABRB2TSHRGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114199975-B Method for evaluating pesticide immunotoxicity based on three-dimensional cell electrochemical sensor 江苏大学 2023-07-18 — — CN claimed
CN-106543078-B A kind of preparation method of quinoline 中国科学院兰州化学物理研究所苏州研究院 2019-01-11 — — CN claimed
CN-105764911-A Luminescent diaza-, monoaza-and benzo-imidazole metal carbene complexes for use in electronic devices such as OLEDs 巴斯夫欧洲公司 2016-07-13 — — CN claimed
CN-103045524-A Vibrio qinghaiensis Q67B and separation, screening and application thereof ZHU WENJIE 2013-04-17 — — CN claimed
CN-114585916-B Method for quantifying compound containing amino group protected with protecting group having Fmoc skeleton 中外制药株式会社 2025-03-11 — — CN disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-07-11 — — US disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 — — US disclosed
US-12024507-B2 Compounds as GLP-1R agonists TERNS PHARMACEUTICALS, INC. (US) 2024-07-02 — — US disclosed
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 — — US disclosed
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 — — US disclosed
CN-1517339-A Pyrazolyl arync 拜尔化学品股份公司 2004-08-04 — — CN disclosed
WO-2003048079-A2 METHOD FOR THE ARYLATION OF OLEFINS BAYER CHEMICALS AG (DE) 2003-06-12 — — WO disclosed
CN-1377394-A Elastic sealing material on the basis of block copolymers made of isobutene and vinyl aromatic monomers BASF AG (DE) 2002-10-30 — — CN disclosed
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 — — US disclosed
EP-1058696-A1 DONOR-MODIFIED OLEFIN POLYMERIZATION CATALYSTS W.R. Grace & Co.-Conn. (US) 2000-12-13 — — EP disclosed
WO-1999043722-A1 DONOR-MODIFIED OLEFIN POLYMERIZATION CATALYSTS W.R. GRACE & CO.-CONN. (US) 1999-09-02 — — WO disclosed
US-5922732-A INSECTICIDES, MITICIDES AND NEMATOCIDES ZENECA LIMITED (GB) 1999-07-13 — — US disclosed
EP-0376145-A2 Method for producing a stereoregular polyolefin Tosoh Corporation (JP) 1990-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024507-B2 Compounds as GLP-1R agonists GLP1R, GIPR, GCGR GABRA1 318/4885GABRB2 376/4885TSHR 80/4885
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 GABRA1 3053/4885GABRB2 3496/4885TSHR 4000/4885
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 GABRA1 4314/4885GABRB2 4386/4885TSHR 1910/4885
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 GABRA1 4226/4885GABRB2 4598/4885TSHR 1403/4885
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use CRBN, CDR2, CRKL GABRA1 563/4885GABRB2 275/4885TSHR 3851/4885
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 GABRA1 3107/4885GABRB2 3675/4885TSHR 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.